Phio Pharmaceuticals Corp (PHIO) Market Cap to Earnings

Corporate emblem and logo of Phio Pharmaceuticals Corp. (PHIO)

Phio Pharmaceuticals leads the field of RNA therapy, having developed the unique INTASYL system to combat melanoma and investing in the modification of immune cells. This price chart on GURU.Markets, where the indicator stands at -0.70, serves as confirmation of the market valuation and is backed by the expertise of a team of genetics and oncology specialists. The scientific community's high level of confidence in targeted intervention methods ensures stable support for the brand's clinical trials.

RXi Pharmaceuticals (PHIO) - Price to Earnings Ratio from 07/04/2022 to 11/13/2026

Comprehensive metric breakdowns and analytics for Phio Pharmaceuticals Corp (PHIO)

- market value and analyst target forecast:
Market Chart RXi Pharmaceuticals|PHIO - Price Target Chart
- market capitalization details:
Market Value Phio Pharmaceuticals Corp.|PHIO - Real Price to Acquire Entire Company
- book value of equity indicators:
Accounting Value of a Share Phio Pharmaceuticals|PHIO - Company Book Value|Market Capitalization to Net Assets phiopharma.com|PHIO - Company Total Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Phio Pharmaceuticals|PHIO - Long-Term Debt to Capital|Short-Term Debt to Capital RXi Pharmaceuticals|PHIO - Company Debts|Debt to Net Assets Ratio Phio Pharmaceuticals Corp.|PHIO - Company Long-Term Debt|Company Current Liabilities Phio Pharmaceuticals|Quick Ratio phiopharma.com
- earnings and valuation multiples indicators:
PHIO - Net Profit|Future Profit Phio Pharmaceuticals|PHIO - P/E Multiple|Projected Price to Earnings Ratio RXi Pharmaceuticals|PHIO - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Phio Pharmaceuticals Corp.|PHIO - Operating profit before deduction of amortization|Earnings per share for the last four quarters Phio Pharmaceuticals|PHIO - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months phiopharma.com|PHIO - Earnings growth in current year|Expected earnings per share growth for next year Phio Pharmaceuticals
- sales volume and revenue indicators:
PHIO - Revenue and Sales Volume|Projected Sales Volume RXi Pharmaceuticals|PHIO - Price-to-Revenue Ratio|Price-to-Projected Revenue Ratio Phio Pharmaceuticals Corp.
Comprehensive company analysis:phiopharma.com - PHIO
Flagship merchandise of Phio Pharmaceuticals Corp

The P/E ratio measures the market value of a single unit of net income, determining the investment payback period and the market's confidence in future cash flows. By analyzing the P/E based on net income, an investor assesses whether Phio Pharmaceuticals (PHIO) expenditures on retaining leading geneticists and DNA analysis AI platforms are justified by the current capitalization over the long term.

Analysis of competing companies

Tempus AI Inc (TEM) - Business Payback Period|Price to Earnings Ratio Qiagen (QGEN)|IONS - Market Cap to Earnings|Repligen Corp. - Price to Earnings Ratio|Company Value to Net Income RNA|CRSP - Price to Earnings Ratio|Market Cap to Net Income WGS|RARE: P/E Multiple|Beam Therapeutics Inc - Company Value to Net Income|SRPT (Sarepta Therapeutics Inc) - P/E Multiple|P/E Multiple Twist Bioscience Corp|Price to Earnings Ratio 10x Genomics, Inc. (TXG)|NTLA (intelliatx.com) - Company Value to Net Income|Price to Earnings Ratio Stoke Therapeutics, Inc. STOK|BLFS - Price to Earnings Ratio|Wave Life Sciences Corp - P/E Multiple|MAZE - P/E Multiple|SION: P/E Multiple|Price to Earnings Ratio primemedicine.com|TSHA (Taysha Gene Therapies, Inc.) - P/E Multiple|Market Cap to Earnings uniQure NV QURE|Price to Earnings Ratio MGTX (MeiraGTx PLC)|P/E Multiple REGENXBIO Corp (RGNX)|Solid Biosciences Inc. - Price to Earnings Ratio|Market Price to Net Income Ratio OCGN (ocugen.com)|PacBio - P/E Multiple|Business Payback Period Benitec Biopharma Inc BNTC|DSGN: P/E Multiple|Price to Earnings Ratio Rocket Corp|FDMT (4D Molecular Therapeutics) - P/E Multiple|P/E Multiple Lexeo|Price to Earnings Ratio Korro Bio, Inc. (KRRO)|Price to Earnings Ratio EDIT (Editas Medicine Inc)|Price to Earnings Ratio Silence Therapeutics Inc. SLN|Business Payback Period ProQR (PRQR)|CDXS - Price to Earnings Ratio|Market Cap to Net Income SGMO|NAUT: P/E Multiple|Metagenomi Inc. - Company Value to Net Income|DTIL (Precision BioSciences, Inc.) - P/E Multiple|Generation Bio Corp (GBIO) - Business Payback Period|Price to Earnings Ratio Boundless Bio, Inc. (BOLD)|XCUR - Market Cap to Earnings|P/E Multiple IMNN (Imunon)|MBIO: Price to Earnings Multiple|RNAZ - Price to Earnings Ratio|BNGO (Bionano Genomics, Inc.) - Price to Earnings Multiple|APDN: P/E Multiple|bluebirdbio.com (BLUE) - P/E Multiple|Price to Earnings Ratio ImmunoPrecise Antibodies Ltd|Omega Therapeutics Inc - Market Cap to Net Income|P/E Multiple OMIC|RGLS (Regulus) - Company Value to Net Income|P/E Multiple SYRS (Syros Pharmaceuticals)|Business Payback Period telesisbio.com (TBIO)|TCON - Price to Earnings Ratio|Market Cap to Earnings Unity Biotechnology Inc.